Loading
A phase 3 trial of Datopotamab deruxtecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations is a phase 3 interventional study registered as NCT07291037 by AstraZeneca, with 400 participants planned, started 2025-10-31 and due to reach its primary completion in 2029-01-29. Interventions recorded: Datopotamab deruxtecan (Dato-DXd), Docetaxel. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Docetaxel, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Datopotamab deruxtecan, AstraZeneca, Antibody-drug conjugate (ADC), Cytotoxic chemotherapy.